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Abstract
Background: The	effect	of	substantive	doses	of	essential	amino	acids	(EAA)	on	in‐
cretin	and	insulin	production,	and	the	impact	of	age	upon	this	effect,	is	ill‐defined.
Methods: A	15‐g	oral	EAA	drink	was	administered	to	young	(N	=	8;	26	±	4.4	years)	
and	older	(N	=	8;	69	±	3.8	years)	healthy	volunteers.	Another	group	of	younger	vol‐
unteers	(N	=	9;	21	±	1.9	years)	was	given	IV	infusions	to	achieve	equivalent	plasma	
amino	 acids	 (AA)	profiles.	Plasma	AA,	 insulin,	 glucagon‐like	peptide‐1	 (GLP‐1)	 and	
glucose‐dependent	insulinotropic	peptide	(GIP)	were	quantified	over	2	hours.
Results: In	 younger	 recruits,	 EAA‐induced	 rapid	 insulinaemia	 and	 aminoacidaemia	
with	total	amino	acids(AA),	EAA	and	branched	chain	amino	acids	 (BCAA)	matched	
between	oral	and	IV	groups.	Insulin	peaked	at	39	±	29	pmol	L−1 at 30 minutes fol‐
lowing	oral	feeding	compared	to	22	±	9	pmol	L−1	at	60	minutes	following	IV	feeding	
(P:	NS).	EAA	peaked	at	3395	μmol	L−1	at	45	minutes	during	IV	infusion	compared	to	
2892 μmol	L−1	following	oral	intake	(Feeding	effect:	P	<	0.0001.	Oral	vs	IV	feeding:	P: 
NS).	There	was	an	11%	greater	increase	in	insulin	levels	in	the	120	minutes	duration	
of	the	study	in	response	to	oral	EAA	as	opposed	to	IV	EAA.	GIP	increased	follow‐
ing	oral	EAA	(452	pmol	L−1	vs	232	pmol	L−1,	P	<	0.05).	Age	did	not	impact	insulin	or	
incretins production.
Conclusion: Postprandial	rises	in	EAA	levels	lead	to	rapid	insulinaemia	which	is	higher	
with	oral	compared	with	IV	EAA,	that	is	attributed	more	to	GIP	and	unaffected	by	
age.	This	finding	supports	EAA,	on	their	own	or	as	part	of	high‐protein	meal,	as	nutri‐
tive therapeutics in impaired glycaemia and ageing.
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1  | INTRODUC TION
Oral glucose has been shown to stimulate greater insulin release 
compared to a comparable glucose challenge given intravenously1 
(measured	as	the	difference	between	insulin	attributed	to	oral	vs	IV	
glucose	load).	This	difference	is	attributed	to	the	secretion	of	incretin	
hormones	such	as	glucagon‐like	peptide‐1	 (GLP‐1)	and	glucose‐de‐
pendent	insulinotropic	peptide	(GIP)—known	as	the	“incretin	effect,”	
produced	 from	the	L	and	K	cells	 respectively,	and	accounts	 for	up	
to	65%	of	the	amount	of	insulin	secreted	following	oral	glucose	in‐
gestion.1,2 Orally ingested lipids have also been shown to induce the 
incretin	effect	due	to	postprandial	elevations	in	both	GLP‐1	and	GIP.3
The extent to which these incretin hormones are produced in 
response	 to	 oral	 intake	 of	 dietary	 proteins	 and	 amino	 acids	 (AA)	
remains	poorly	defined.	Nonetheless,	 it	has	been	shown	that	con‐
sumption	of	a	mixture	of	oral	amino	acids	(AA)	stimulates	GLP‐1	and	
GIP	 secretion.4	Moreover,	 in	 the	only	 study	assessing	 the	 true	 in‐
cretin	effects	of	AA,	Lindgren	et	al5 reported an incretin effect of 
~25%	attributed	mainly	to	rises	in	GIP	(rather	than	GLP‐1)	following	
a	small	dose	(6.5	g)	of	mixed	(ie,	essential	AA	[EAA]	and	non‐EAA)	vs	
comparable	I.V	AA	administration.	Since	the	estimated	daily	protein	
requirement	for	a	70	kg	adult	is	0.8	g	kg−1 d−1,6 studies to investigate 
the	 impact	of	more	 typical	AA	meal	 intake	of	>10	g	of	AA	 (~20	g	
protein)	 on	 incretin	 hormones	 production	 is	 important.	Moreover,	
determining	the	effects	of	EAA	vs	NEAA	on	insulin	production	is	im‐
portant	in	relation	to	determining	the	key	AA	drivers	of	the	incretin	
hormone productions.
Ageing	of	the	gut	and	gut‐brain	axis	is	a	burgeoning	area	of	re‐
search.	 Ageing	 is	 associated	 with	 reduced	 energy	 intake,	 protein	
malnutrition	(in	some	instances)	and	impaired	anabolic	responsive‐
ness to protein foods7‐12; likely contributing to deleterious shifts in 
body	composition—engendering	sarcopenia,	age‐related	 insulin	 re‐
sistance	and	metabolic	 ill‐health.13 These factors are facilitated by 
age‐related	changes	 in	gastrointestinal	 (GI)	physiology	 in	 response	
to mixed meal14‐16—which	could	play	an	 important	 role	 in	nutrient	
deficiency	and	predisposition	to	age‐related	sarcopenia.	Yet	the	ef‐
fects	of	EAA	alone	on	incretin	and	insulin	hormone	production,	and	
in	relation	to	age,	remains	poorly	defined.	Crucially,	while	oral	lipid	
and	glucose	intake	did	not	lead	to	differences	in	either	L	and	K	cells	
responses	in	younger	and	older	people,17 older individuals exhibited 
higher	levels	of	GIP	(not	GLP‐1)	compared	to	younger	subjects	after	
oral protein consumption.18
In	 the	 postabsorptive	 state,	 mobilization	 of	 NEAA	 (mainly	
glutamate	 and	 alanine)	 from	 skeletal	 muscle	 represent	 the	 main	
mechanism via which splanchnic tissues are provided with fuel at 
the expense of negative muscle protein balance.19 During the fed 
state,	 splanchnic	 tissues	 rely	 on	 enteral	 extraction	 of	 glutamine	
and	alanine	with	most	EAA	appearing	in	the	systemic	circulation.20 
Therefore,	EAA,	due	 to	 their	 lesser	 influence	on	 splanchnic	 tissue	
gluconeogenesis,	 could	be	 regarded	as	 an	 important	nutraceutical	
strategy for the regulation of muscle and glucose metabolism. In ad‐
dition,	this	later	fact	makes	EAA	a	suitable	testing	mixture	to	allow	
more	accurate	estimation	of	protein‐derived	incretin	secretion.	Also,	
since	EAA	are	 the	primary	drivers	of	muscle	protein	synthesis21‐23 
while	incretin	hormones	are	critical	to	glucose	metabolism,	studies	
investigating	 the	effects	of	 oral	 vs	 intravenous	EAA	 in	 relation	 to	
incretin hormones are relevant to promoting healthy ageing. The aim 
of	this	study	was	thus	to	investigate:	(a)	the	extent	oral	EAA	could	
induce	increases	in	incretin	and	insulin	hormone	production,	and	(b)	
if	ageing	impacts	upon	these	postulated	EAA‐induced	effects.
2  | SUBJEC TS AND METHODS
2.1 | Study design
The	 study	 was	 approved	 by	 The	 University	 of	 Nottingham	 Ethics	
Committee	and	Hamilton	Integrated	Research	Ethics	Board	and	was	
conducted	 in	 line	with	the	Declaration	of	Helsinki	and	registered	at	
https	://clini	caltr	ials.gov/	(NCT02370745).	A	total	of	25	healthy	volun‐
teers	were	 recruited	 to	participate.	Seventeen	healthy	young	males	
(18‐30	 years)	 and	 eight	 healthy	 older	males	 (65‐75	 years)	 were	 re‐
cruited	via	local	advertisement	in	the	two	sites	of	the	study	(University	
of	 Nottingham—Derby—UK	 and	 McMaster	 University—Hamilton—
Canada).	All	 volunteers	 gave	 informed	consent.	All	 participants	had	
no	 history	 of	 diabetes,	 liver	 disease	 or	 gastrointestinal	 abnormali‐
ties.	They	were	assigned	to	three	groups.	 (a)	Young	oral	 (Y.O)	group	
(Nottingham	site):	 eight	 young	aged	 to	have	oral	EAA	beverage.	 (b)	
Young	 intravenous	 (Y.IV)	 group	 (Hamilton	 site):	 nine	 young	 aged	 to	
have	equivalent	intravenous	EAA.	(c)	Old	oral	(O.O)	group	(Nottingham	
site):	eight	older	aged	to	have	the	same	oral	EAA	beverage	as	the	Y.O	
group. Please see Table 1 for the subjects' characteristics.
All	groups	reported	to	the	study	sites	following	overnight	fasting	
of	8‐14	hours.	An	18‐20G	cannula	was	inserted	into	the	antecubital	
vein for blood sampling at baseline (t	=	0	minute)	and	at	15,	30,	45,	
60,	75,	90,	105	and	120	minutes	post	 consumption	of	either	15	g	
of	oral	EAA	solution	 (YO	and	OO	groups)	or	 following	 initiation	of	
TA B L E  1   Characteristics of study participants
Parameter 
(mean ± SD) Y.O (n = 8) Y.IV (n = 9) O.O (n = 8) P
Age	(y) 26	±	4.4 22	±	1.9 69	±	3.8 ****
Height	(m) 1.80	±	0.1 1.79	±	0.03 1.70	±	0.1 *
Body	mass	(kg) 81.0	±	11.8 78.1	±	8.8 75.8	±	5.1 NS
BMI	(kg	m−2) 25.0	±	2.8 24.4	±	2.8 25.5	±	1.9 NS
FPG 4.3	±	0.9 4.4	±	0.6 4.9	±	1.0 NS
Abbreviations:	FPG,	fasting	plasma	glucose;	NS,	not	significant;	O.O,	
older	group	consumed	oral	EAA;	Y.IV,	young	group	given	intravenous	
EAA;	Y.O,	young	group	consumed	oral	EAA.
****P	<	0.0001	O.O	vs	Y.O	and	O.O	vs	Y.IV.	
*P	<	0.05	O.O	vs	Y.O	and	O.O	vs	Y.IV.	
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intravenous	15	g	of	equivalent	EAA	infusion	(group	Y.IV.).	After	base‐
line	 sampling,	 volunteers	 (YO	and	OO	groups)	were	 asked	 to	 con‐
sume	a	pre‐prepared	oral	EAA	beverage.	The	solution	was	prepared	
the	day	before	in	250	mL	of	aqueous	solution,	kept	refrigerated	over‐
night and warmed to room temperature in the morning of the study. 
The	stability	of	the	EAA	components	of	the	solution	following	over‐
night	stay	was	tested	beforehand.	The	composition	of	the	EAA	bev‐
erage was l‐histidine:	1.21	g;	 l‐isoleucine:	1.73	g;	 l‐leucine:	3.59	g;	
l‐lysine:	3.07	g;	l‐methionine:	0.95	g;	l‐phenylalanine:	0.91	g;	l‐thre‐
onine: 1.13 g; l‐tryptophan:	0.48	g	and	l‐valine	1.86	g.24	Following	
the	 last	 sample	 (120	minutes),	 the	 cannula	 was	 removed	 and	 vol‐
unteers were offered a snack. Participants were kept at the study 
site for 30 minutes observation before being allowed to leave. The 
group	of	eight	young	males	 receiving	an	 intravenous	equivalent	of	
15	g	EAA	(Stepping	Hill	Hospital	pharmacy,	Stockport,	UK)	received	
two cannulae; one for blood sampling as described above and the 
second	for	infusion	of	EAA.	The	EAA	infusate	contained	equivalent	
amounts	of	EAA	to	the	oral	beverage.	EAA	were	infused	for	a	total	
of	60	minutes.	Following	sampling	for	baseline	measurements,	EAA	
infusion was started at a rate of 133 mg min−1 for 15 minutes after 
which the rate of infusion was increased to 289 mg min−1. These rates 
were	calculated	aiming	to	deliver	13%	of	total	EAA	 infusate	 in	the	
first	15	minutes	and	87%	over	the	remaining	45	minutes	guided	by	
previous reports.5	With	the	start	of	infusion,	volunteers	were	given	
250	mL	H2O	to	compensate	 for	stomach	distention.	At	 the	end	of	
infusion	 (60	minutes),	 blood	 sampling	 continued	 every	15	minutes	
for	another	hour	to	complete	a	total	of	120	minutes	of	sampling.	At	
the	end	of	the	study,	cannulae	were	removed	and	volunteers	were	
offered a snack. They remained on site for monitoring as described 
above.	See	Figure	1	 for	 the	schematic	 representation	of	 the	study	
protocol.
2.2 | Measurements and calculations
2.2.1 | Measurement of plasma AA and glucose 
concentrations
For	measurement	of	AA	concentrations,	 internal	standards	were	
added to plasma samples before the addition of urease solution 
and	 incubation	 at	 room	 temperature	 for	 20	 minutes.	 Samples	
were	then	de‐proteinized	with	ice‐cold	ethanol	for	20	minutes	at	
4°C,	before	centrifugation	at	13	000	g.	The	plasma	AA	containing	
supernatant was then decanted into boiling tubes and evaporated 
at 90°C under N2.	Dried	AA	were	vortex	mixed	in	0.5	mol	L
−1	HCl	
and	lipids	extracted	in	Ethyl	Acetate,	before	evaporation	to	dry‐
ness.	AA	were	derivatized	through	the	addition	of	equal	volumes	
of	acetonitrile	 (ACN)	and	N‐tert‐Butyldimethylsilyl‐N‐methyltrif‐
luoroacetamide	 (MTBSTFA)	and	heated	 to	90°C	 for	60	minutes.	
Samples	 were	 allowed	 to	 cool	 before	 transfer	 to	 autosampler	
vials.	Glucose	concentrations	were	determined	similarly	through	
the inclusion of an internal standard before the samples were 
de‐proteinized	with	 ice‐cold	ethanol	and	evaporated	to	dryness.	
Accurate	analysis	of	glucose	by	GC‐MS	 is	 routine	 to	our	 labora‐
tories	as	 final	batch	analyses.	Samples	were	collected	 in	sodium	
fluoride	 tubes,	 stored	 immediately	 on	 ice,	 centrifuged	 in	 small	
batches	throughout	the	study,	then	aliquoted	and	stored	at	−80°C	
until	 analysis	 by	 GC‐MS.25	 Glucose	 samples	 were	 derivatized	
through	 the	 addition	 of	 oxime	 reagent	 to	 dried	 samples,	 vortex	
mixed	 and	 heated	 at	 85°C	 for	 30	 minutes,	 before	 the	 addition	
of	N,O‐Bis(trimethylsilyl)trifluoroacetamide	 (BSTFA)	 and	 further	
heated	at	85°C	for	30	minutes.	Both	AA	and	glucose	concentra‐
tions	were	quantified	against	a	standard	curve	of	known	concen‐
trations	using	GC‐MS.
2.2.2 | Measurement of insulin and gut hormones 
F I G U R E  1  Schematic	representation	
of the study protocol. Eight young and 
eight older male volunteers orally ingested 
a total of 15 g essential amino acids 
(EAA).	Another	group	of	nine	young	male	
volunteers received 15 g of intravenous 
EAA	infusion
4 of 11  |     ABDULLA et AL.
concentrations
Commercial	 ELISA	 kits	 (Milliplex	 Map	 kit;	 EMS	 Millipore)	 were	
used	to	determine	 insulin	and	gut	hormone	concentrations.	Blood	
samples	for	these	analysis	were	collected	in	P800	tubes,	that	spe‐
cifically	 stabilize	GLP‐1	 and	GIP	 upon	 collection.	 The	 kit	was	 the	
Milliplex	Map	Kit—Human	metabolic	hormone	magnetic	bead	panel	
(Cat	 #HMHEMAG‐34K)	 measured	 on	 a	 Luminex‐Magpix.	 This	 is	
commercially validated kit that has been certified to have a linear 
range	for	GLP‐1	of	2.7‐2000	mg	mL−1	and	for	GIP	1.4‐1000	pg	mL−1,	
both	shown	to	have	a	recovery	of	103%	from	serum	matrix.	The	ana‐
lytes	were	 insulin,	C‐peptide,	GIP	total,	GLP‐1	total	and	glucagon.	
F I G U R E  2  Plasma	total	AA	(A),	EAA	(B)	and	BCAA	(C)	concentrations	after	oral	vs	IV	EAA,	demonstrated	with	AUC	in	(D),	(E)	and	
(F),	respectively.	aGreater	than	respective	baseline	(P	<	0.05).	Main	effect	of	feeding,	P	<	0.0001;	effect	of	feeding	type,	NS;	Interaction,	
P	<	0.05.	Values	are	expressed	as	mean	±	SD.	Measured	by	2‐way	ANOVA.	AA,	amino	acids;	BCAA,	branched‐chain	amino	acids;	EAA,	
essential amino acids
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The incretin effect was calculated as the difference between insulin 
responses	 after	 oral	 and	 intravenous	 EAA	 stimulation,	 relative	 to	
the	response	seen	after	oral	EAA	ingestion.
2.3 | Power of calculation and statistical analysis
The	 sample	 size	 was	 prospectively	 determined	 with	 a	 power	 of	
calculation	and	taking	a	population	(inter‐	and	intraindividual)	vari‐
ance	of	15%	(based	on	previous	laboratory	data	on	insulin	and	AA	
concentrations	on	young	and	old	individuals)	and	CV	of	laboratory	
techniques	also	of	15%	to	detect	differences	in	feeding	modes	with	
80%	confidence	at	the	5%	significance	level.	The	analysis	was	con‐
ducted	using	Prism	7	(GraphPad).	Data	are	presented	as	mean	±	SD.	
Normality	of	distribution	was	tested	using	D'Agostino	and	Pearson	
Omnibus normality tests. Comparison between two measures 
made at times before and after feeding or same time point between 
two	groups	were	made	via	repeated	measures	2‐way	ANOVA	with	
Bonferroni	 post‐test	 analysis	 to	 determine	 significance.	 Change	
from baseline was calculated as the ratio between time point meas‐
urement and calculated average baseline value. The net incremental 
area	under	the	response	curve	(AUC)	was	calculated	for	each	indi‐
vidual	separately	and	presented	as	a	two‐group	comparison.
3  | RESULTS
3.1 | Plasma AA concentrations
For	both	Y.O	and	Y.IV	groups,	concentrations	were	matched	with	no	
significant difference between the two groups at baseline for total 
AA,	EAA	and	branched‐chain	amino	acid	 (BCAA;	Figure	2—results	
evaluated	via	RM	2‐way	ANOVA).	Total	AA,	EAA	and	BCAA	were	
significantly higher than correspondent baseline values at 15 min‐
utes (P	 <	 0.05)	 in	 both	 groups	 with	 exception	 of	 total	 AA	 in	 Y.O	
group,	which	started	to	become	significantly	higher	at	30	minutes.	
Total	AA	reached	a	peak	of	5170	±	1654	μmol	L−1	(1‐fold	rise	from	
baseline)	in	Y.IV	group	compared	to	a	peak	of	4523	±	487	μmol	L−1 
(0.9	 fold	 rise)	 in	 Y.O	 group	 at	 45	minutes	 (P:	 NS).	 EAA	 peaked	 at	
3395	 ±	 1072	 μmol	 L−1	 (2.3	 fold	 rise	 from	 baseline)	 at	 45	minutes	
during	 IV	 infusion	compared	 to	2891	±	350	μmol	L−1 (2.1 fold rise 
from	baseline)	 following	oral	 intake	 (P:	NS).	BCAA	reached	a	peak	
of	 1678	±	401	μmol	 L−1	 (2.7‐fold	 rise	 from	baseline)	 in	Y.IV	 group	
compared	to	1330	±	284	μmol	L−1	(2.6‐fold	rise	from	baseline)	in	the	
Y.O	group	at	60	minutes	(P:	NS).	Non‐essential	amino	acid	(NEAA)	
concentrations remained unchanged from baseline in both groups 
throughout	the	120‐minute	duration	of	the	study.	Total	AA	concen‐
trations	 returned	 to	 baseline	 at	 120	minutes	 in	 Y.O	 group,	 as	 op‐
posed	to	105	minutes	in	the	Y.IV	group.	Total	EAA	and	BCAA	were	
back	to	baseline	at	105	and	120	minutes,	respectively.
There	was	no	significant	difference	between	individual	EAA	con‐
centrations at all time points with the exception of threonine and 
histidine	 in	 the	Y.IV	at	45	and	60.	However,	change	 from	baseline	
was not different for threonine at these time points.
3.2 | Glucose, insulin, C‐peptide and glucagon
Analyses	were	conducted	in	Y.O	and	Y.IV	groups.	There	was	no	dif‐
ference in glucose concentration between the two young groups at 
baseline.	Insulin	peaked	at	39	±	29	pmol	L−1	at	30	minutes	in	the	Y.O	
group,	which	was	significantly	elevated	compared	to	baseline	(2.3‐
fold	rise	from	baseline,	P	<	0.05).	In	comparison,	insulin	concentra‐
tions	in	Y.IV	group	peaked	at	22	±	9	pmol	L−1	at	60	minutes	(0.4‐fold	
rise	from	baseline)	and	overall	remained	not	different	from	baseline	
throughout the study. The difference in insulin rise between the two 
groups	(the	incretin	effect)	was	45%	calculated	as	the	difference	be‐
tween	AUC	for	the	first	60	minutes	and	was	11%	calculated	as	AUC	
difference	for	the	entire	120	minutes	duration	of	the	study.	C‐pep‐
tide	change	at	30	minutes	from	baseline	was	1.7	±	0.7	folds	(P < 0.5 
vs	baseline)	 in	 the	Y.O	group	 compared	 to	1.3	±	0.8	 folds	 change	
from baseline (P:	NS	against	baseline)	in	the	Y.IV	group	with	no	sig‐
nificant difference between the two groups at this time point. This 
rise	corresponded	to	that	seen	in	 insulin	concentrations.	Glucagon	
concentrations rose from baseline peaking at 30 minutes following 
oral	EAA	intake	 (2	fold	rise,	P:	NS)	and	at	60	minutes	following	IV	
EAA	administration	(1.8	fold	rise,	P:	NS;	Figure	3).
3.3 | Incretin hormones
Total	GLP‐1	concentrations	rose	significantly	compared	to	baseline	
at	30	minutes	(0.8‐fold	rise	from	baseline)	in	the	Y.O	group	(136	±	41	
vs	74	±	20	pmol	L−1,	P	<	0.05).	In	comparison,	GLP‐1	concentrations	
in	 the	 Y.IV	 group	 stayed	 unchanged	 through	 the	 120‐minute	 du‐
ration of the study. No difference was observed between feeding 
types	 in	GLP‐1	 concentrations.	 Total	GIP	 concentrations	 rose	 sig‐
nificantly	following	oral	consumption	to	peak	at	30	minutes	(1.6	fold	
rise	from	baseline)	while	remaining	unchanged	throughout	the	study	
in	the	Y.IV	group.	This	rise	was	significantly	different	between	the	
two	groups	(399	±	173	vs	205	±	68	pmol	L−1,	P	<	0.05;	Figure	3).
3.4 | Ageing and AA acid profile
Following	 oral	 consumption	 of	 EAA	beverage	 in	 the	Y.O	 and	O.O	
groups,	 AA	 profiles	 were	 similar	 between	 the	 two	 groups	 at	 all	
time	points.	At	15	minutes,	total	AA,	EAA	and	BCAA	were	signifi‐
cantly	 elevated	 compared	 to	 baseline.	 Total	 AA,	 EAA	 and	 BCAA	
peaked	at	60	minutes	 in	both	groups	 (Y.O	vs	O.O:	4357	±	659	vs	
4868	 ±	 1402	 μmol	 L−1,	 2716	 ±	 513	 vs	 3214	 ±	 858	 μmol	 L−1 and 
1330	±	284	vs	1632	±	386	μmol	L−1,	respectively,	P:	NS)—Figure	4.
3.5 | Ageing and incretin hormone release
Insulin,	 GLP‐1	 and	 GIP	 rose	 similarly	 between	 Y.O	 and	 O.O	
groups	 in	 response	 to	 oral	 consumption	 of	 EAA.	 All	 hormones	
peaked	at	30	minutes	 (67	±	50	vs	68	±	35	pmol	L−1,	246	±	101	vs	
261	±	109	pmol	L−1	and	594	±	264	vs	538	±	99	pmol	L−1;	Y.O	vs	O.O	
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for	insulin,	GLP‐1	and	GIP,	respectively,	P:	NS)	with	a	slower	return	
to	baseline	in	the	O.O	group	(Figure	5).
4  | DISCUSSION
In	this	study,	we	report	that	15	g	of	orally	consumed	EAA	increased	
plasma insulin concentrations which are higher following oral com‐
pared	with	IV	EAA	challenge.	We	are	not	aware	of	any	other	study	
that	examined	such	an	effect	 in	 relation	 to	EAA.	This	 rise	and	 fall	
F I G U R E  3  Oral	vs	IV	EAA.	Plasma	insulin,	incretin	hormone	concentrations,	C‐peptide,	glucagon	and	glucose.	Insulin	(A),	GIP	(B)	and	
GLP‐1	(C).	C‐peptide	and	glucagon	changes	from	baseline	are	plotted	in	(D)	and	(E)	respectively.	Glucose	concentrations	are	shown	in	
(F).	aGreater	than	respective	baseline	(P	<	0.05).	bBetween	feeding	types	(P	<	0.05).	Values	are	expressed	as	mean	±	SD.	C‐peptide	and	
glucagon	data	are	displayed	as	ratio	from	baseline	mean.	Measured	by	2‐way	ANOVA.	EAA,	essential	amino	acids;	GIP,	glucose‐dependent	
insulinotropic	peptide;	GLP‐1,	glucagon‐like	peptide‐1
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in	insulin	was	matched	by	a	significant	rise	followed	by	a	fall	in	GIP.	
GLP‐1	also	had	risen	significantly	from	baseline	but	the	fact	that	insu‐
lin	levels	fell	despite	the	continued	elevation	of	GLP‐1	concentration	
points to lack of causal effect. The difference in insulin concentra‐
tion	with	oral	vs	IV	is	likely	to	be	attributed	the	incretin	hormones	
(and	likely	GIP)	was	~11%	calculated	as	total	AUC	over	120	minutes.	
This	 effect	 is	 EAA‐related	 since	 no	 gluconeogenic	 source	was	 in‐
fused in our study. It is also important to highlight the use of a dose 
(15	g	EAA)	relating	to	main	meal	protein	consumption	and	thus	any	
reported results could be easily extrapolated to translate clinically if 
an	equivalent	EAA	beverage	is	provided	instead.	Finally,	our	studies	
have demonstrated that this effect of incretin hormone production 
F I G U R E  4  Young	vs	Old	plasma	AA	profile.	Plasma	concentrations	of	total	AA	(A),	total	EAA	(C)	and	BCAA	(E)	plotted	alongside	AUC	in	
(B),	(D)	and	(F),	respectively.	aGreater	than	respective	baseline	(P	<	0.05).	Main	effects	of	feeding,	P	<	0.0001,	effects	of	age,	NS,	Interaction,	
NS.	Values	are	expressed	as	mean	±	SD.	Measured	by	2‐way	ANOVA
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(at	least	in	response	to	EAA)	does	not	appear	to	be	affected	by	the	
process of physiological ageing.
Incretin and insulin responses to protein are established.26 
Nonetheless,	excluding	a	single	study	by	Lindgren	et	al,5 the effect of 
AA	on	incretin	hormones	release	remains	poorly	defined.	Moreover,	
this	previous	study	employed	AA	mixtures,	containing	both	essential	
and	non‐essential	AA.	This	could,	in	theory,	be	problematic	when	it	
comes	to	assessing	the	“incretin	effects”	as	some	NEAA	are	known	to	
be	gluconeogenic	precursors,	namely	alanine	(kidney)	and	glutamine	
(liver	and	intestine).	Indeed,	glutamine	is	the	main	source	of	energy	
for	the	gut,	especially	the	small	intestine,	through	the	gluconeogenic	
production of glucose.27	Therefore,	any	quantification	of	an	“incretin	
effect”	would	be	difficult	to	ascribe	solely	to	AA.	The	use	of	EAA	in	
this study represents a novel approach to avoid this potential con‐
founder	while	focusing	upon	the	impacts	of	diet‐derived	(essential)	
AA	components	of	dietary	protein.
Stimulation	of	GIP	but	not	GLP‐1	by	oral	protein	 ingestion	has	
been reported previously.28 Enteroendocrine cells are scattered 
along the length of the gut making it the largest endocrine organ in 
the	body.	In	our	study,	GLP‐1	in	both	Y.O	and	Y.IV	rose	comparably	
from baseline. The fact that there was no change in insulin concen‐
tration	in	the	Y.IV	group	makes	insulin	rise	in	the	Y.O	group	highly	
F I G U R E  5  Young	vs	Old	plasma	insulin	and	incretin	hormone	release	following	oral	consumption	of	15	g	EAA.	Insulin	(A),	GIP	(B)	and	
GLP‐1	(C)	concentrations,	demonstrated	with	AUC	in	(D),	(E)	and	(F),	respectively.	aGreater	than	respective	baseline	(P	<	0.05).	Main	effects	
of	feeding,	P	<	0.0001;	effects	of	age,	NS;	Interaction,	NS.	Values	are	expressed	as	mean	±	SD.	Measured	by	2‐way	ANOVA.	EAA,	essential	
amino	acids;	GIP,	glucose‐dependent	insulinotropic	peptide;	GLP‐1,	glucagon‐like	peptide‐1
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unlikely	contributed	to	by	GLP‐1.	Most	likely	GLP‐1	concentrations	
achieved in both modalities of feeding are not high enough to stim‐
ulate	 insulin	 secretion.	 This	 lack	 of	 GLP‐1‐mediated	 insulin	 secre‐
tion following protein intake might be related to absorption sites in 
the	bowel;	K	cells	are	predominantly	present	in	the	duodenum	and	
ileum.	By	the	time	AA	reaches	the	jejunum,	where	L	cells	are	more	
predominant,	there	might	be	very	little	substrate	left	to	stimulate	L	
cells.	Another	explanation	could	be	that	L	cells	are	not	as	sensitive	
to	AA	compared	to	K	cells.	This	does	not	exclude	a	small	contribu‐
tory	effect	for	GLP‐1	on	insulin	secretion	from	neuronal	stimulation	
within	the	gut.	In	contrast	to	this,	data	from	mice	and	cell	cultures	
reported	evidence	of	an	AA‐stimulated	GLP‐1	release,	namely	gluta‐
mine,	glycine,	alanine	and	phenylalanine.29
Our	results	show	that	providing	15	g	of	EAA	stimulates	glucagon	
production,	although	the	rise	overall	was	not	significantly	different	
from	 baseline.	 Glucagon	 stimulation	 was	 previously	 reported	 fol‐
lowing	mixed	AA	and	whey	protein.30,31	 It	was	suggested	 that	AA	
and glucagon regulate each other in a feedback loop that involves 
α‐cells	 and	hepatocytes.32	 In	 comparison	 to	AA,	 orally	 or	 intrave‐
nously	 delivered	 glucose	 suppresses	 glucagon	 secretion,	 which	 is	
more pronounced with the latter mode of delivery.2 Incretin hor‐
mones	have	a	contrasting	effect	on	glucagon.	While	GIP	stimulates	
glucagon secretion from pancreatic α‐cells,	GLP‐1	inhibits	its	release.	
Further,	pancreatic	α‐cells	are	known	to	have	a	very	small	number	of	
GLP‐1	receptors	compared	to	GIP	receptors,	which	are	ubiquitously	
expressed within α‐cells.33	Compared	to	glucose	consumption,	the	
contrasting glucagon response seen in this study is likely a response 
to	rises	in	EAA	concentration.	Incretin	release	as	a	result	of	oral	con‐
sumption seems to have no added effect on glucagon release.
The effect of incretin hormones on insulin production is crucial 
in alleviating postprandial hyperglycaemia in normal individuals. In 
individuals	with	type	2	diabetes	where	this	effect	is	impaired,1 strat‐
egies that potentiate insulin secretion are vital in controlling post‐
prandial	blood	glucose	excursions.	Further,	postprandial	glycaemia	
has	proven	to	be	a	better	predictor	for	HbA1c	compared	to	fasting	
blood glucose.34	 Therefore,	 although	 our	 study	was	 performed	 in	
normoglycaemic	individuals,	we	believe	that	optimising	AA	mixtures	
could represent a feeding strategy for individuals with impaired gly‐
caemia.	For	example,	a	previous	study	has	shown	that	consumption	
of whey protein prior to a standard breakfast was associated with a 
significant	reduction	in	postprandial	glucose,	driven	by	increased	in	
post	prandial	GLP‐1	and	insulin	concentration	compared	with	con‐
trol.35	The	amount	of	15	g	of	EAA	in	our	study	also	ensures	that	a	
sufficient	meal	portion	is	delivered	per	meal	 in	a	daily	AA	require‐
ment	 of	 24‐56	 g	 of	 protein	 per	 day	 for	 a	 70	 kg	 adult.	 In	 addition	
to	this	antiglycaemic	property	showed	 in	our	study,	EAA	have	the	
advantage	of	superior	“anabolic	profile”	compared	to	other	dietary	
protein mixes.36
We	acknowledge	that	the	lack	of	cross‐over	comparison	could	be	
a	potential	source	for	variability	between	the	two	young	groups.	We	
also acknowledge the fact that the physiological process of diges‐
tion	and	absorption	is	subject	to	both	intra	and	inter‐individual	vari‐
ations	and	that	a	cross‐over	design	may	have	been	more	powerful.	
However,	 we	 think	 the	 well‐matched	 plasma	 appearance	 of	 EAA	
across the groups and the greater capture of biological variance are 
validatory and study strengths.
We	did	not	detect	age‐related	differences	in	gut	hormone	re‐
sponses	 to	 EAA.	 This	 finding	 suggests	 that,	 despite	 adverse	 re‐
ports	 on	 ageing	 related	 gut	 physiology,37‐39 the function of gut 
incretin	secretion,	at	least	in	response	to	EAA,	remains	largely	in‐
tact with ageing.18	Nonetheless,	older	age	did	appear	to	be	related	
to	 a	 slower	 return	 (albeit	 not	 significant)	 of	 incretin	 and	 insulin	
to	baseline	following	oral	consumption	(Y.O	and	O.O	groups);	we	
suspect	 this	may	be	due	 to	 increased	 rates	of	 clearance	of	EAA	
in	 the	young.	 In	 contrast,	AA	profiles	were	also	 similar	between	
both	age	groups	indicating	that	digestion,	absorption	and	splanch‐
nic	extraction	of	EAA	is	minimally	affected	by	the	ageing	process.	
Therefore,	nutritional	strategies	aimed	at	improving	health	perfor‐
mance and skeletal muscle health in the older population should 
focus	on	the	quality	of	diet	and	appetite	enhancement.	Future	di‐
rections could aim at further scrutinising the mechanisms by which 
EAA	 stimulate	 L	 cells	 and	whether	 this	 could	 be	 translated	 into	
more	potent	stimulation	(ie,	higher	GLP‐1	concentration)	as	a	re‐
sult	of	EAA	mixture	consumption.
5  | CONCLUSION
We	have	shown	that	EAA	are	able	to	induce	rises	in	incretins	and	in‐
sulin	hormones.	There	was	a	demonstrable	differential	effect	of	EAA	
on insulin production when given orally and matched with an intra‐
venous	 equivalent.	Our	 results	 also	 suggest	 that	 an	 EAA‐induced	
effect	is	delivered	through	hormonal	rises	likely	related	to	GIP.	Our	
results add to those from a series of studies previously proved that 
the	“incretin	effect”	exists	following	consumption	of	glucose,	mixed	
AA	 and	 lipid	 beverage.	 In	 particular	 relation	 to	AA‐induced	 incre‐
tin	hormone	production,	we	suggest	using	EAA	gives	more	accurate	
estimate in this regards. Our results suggest that the process of 
physiological	ageing	does	not	adversely	affect	EAA‐induced	 incre‐
tin	hormone	release.	Hence	(although	it	was	not	directly	estimated	
in	 this	 study),	we	predict	 that	 associated	 incretin	 effect	 in	 elderly	
population	 is	 likely	to	remain	 intact.	Further	research	 is	needed	to	
inform clinically or nutritionally meaningful intervention especially 
that	could	elucidate	the	mechanisms	via	which	L	and	K	cells	sense	
EAA	in	the	gut	and	EAA‐mediated	hormones	release	in	both	youth	
and ageing.
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